close

A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies

A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies Orgenesis, a global US biotech company developing personalized therapies and closed processing systems through its Cell & Gene Therapy (CGT) Biotech Platform, announced a research and development collaboration with Hospital Infantil…..

New R&D agreement to expand Ziopharm’s TCR-T Program

New R&D agreement to expand Ziopharm's TCR-T Program Ziopharm Oncology, an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral Sleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy, has concluded a new R&D agreement with MD Anderson Cancer Center. This agreement is related…..